|
1
|
Gadgeel SM: Personalized therapy of
non-small cell lung cancer (NSCLC). Adv Exp Med Biol. 890:203–222.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Califano R, Romanidou O, Mountzios G,
Landi L, Cappuzzo F and Blackhall F: Management of NSCLC disease
progression after first-line EGFR tyrosine kinase inhibitors: What
are the issues and potential therapies? Drugs. 76:831–840. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ameis D, Khoshgoo N, Iwasiow BM, Snarr P
and Keijzer R: MicroRNAs in lung development and Disease. Paediatr
Respir Rev. 22:38–43. 2017.PubMed/NCBI
|
|
4
|
Singh S, Zheng Y, Jagadeeswaran G, Ebron
JS, Sikand K, Gupta S, Sunker R and Shukla GC: Deep sequencing of
small RNA libraries from human prostate epithelial and stromal
cells reveal distinct pattern of microRNAs primarily predicted to
target growth factors. Cancer Lett. 371:262–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zoni E and van der Pluijm G: The role of
microRNAs in bone metastasis. J Bone Oncol. 5:104–108. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masotti A, Miller MR, Celluzzi A, Rose L,
Micciulla F, Hadoke PW, Bellucci S and Caporali A: Regulation of
angiogenesis through the efficient delivery of microRNAs into
endothelial cells using polyamine-coated carbon nanotubes.
Nanomedicine. 12:1511–1522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin L, Zhang YD, Chen ZY, Chen Y and Ren
CP: The clinicopathological significance of miR-149 and PARP-2 in
hepatocellular carcinoma and their roles in chemo/radiotherapy.
Tumour Biol. 37:12339–12346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo G, Chao YL, Tang B, Li BS, Xiao YF,
Xie R, Wang SM, Wu YY, Dong H, Liu XD, et al: miR-149 represses
metastasis of hepatocellular carcinoma by targeting
actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao D, Jia Z, You L, Wu Y, Hou Z, Suo Y,
Zhang H, Wen S, Tsukamoto T, Oshima M, et al: 18β-glycyrrhetinic
acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1
signaling. Oncotarget. 7:71960–71973. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao F, Bian F, Ma X, Kalinichenko VV and
Das SK: Control of regional decidualization in implantation: Role
of FoxM1 downstream of Hoxa10 and cyclin D3. Sci Rep. 5:138632015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen PM, Wu TC, Shieh SH, Wu YH, Li MC,
Sheu GT, Cheng YW, Chen CY and Lee H: MnSOD promotes tumor invasion
via upregulation of FoxM1-MMP2 axis and related with poor survival
and relapse in lung adenocarcinomas. Mol Cancer Res. 11:261–271.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen YY, Huang TW, Tsai WC, Lin LF, Cheng
JB, Chang H and Lee SC: Risk factors of postoperative recurrences
in patients with clinical stage I NSCLC. World J Surg Oncol.
12:102014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhijun Z and Jingkang H: MicroRNA-520e
suppresses non-small-cell lung cancer cell growth by targeting
Zbtb7a-mediated Wnt signaling pathway. Biochem Biophys Res Commun.
486:49–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo Y, Sun W, Gong T, Chai Y, Wang J, Hui
B, Li Y, Song L and Gao Y: miR-30a radiosensitizes non-small cell
lung cancer by targeting ATF1 that is involved in the
phosphorylation of ATM. Oncol Rep. 37:1980–1988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim IM, Ackerson T, Ramakrishna S,
Tretiakova M, Wang IC, Kalin TV, Major ml, Gusarova GA, Yoder HM,
Costa RH, et al: The Forkhead Box m1 transcription factor
stimulates the proliferation of tumor cells during development of
lung cancer. Cancer Res. 66:2153–2161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M,
Guo YH, Shi J, Gong XD, Zhu YL, Liu F, et al: Overexpression of
FOXM1 is associated with EMT and is a predictor of poor prognosis
in non-small cell lung cancer. Oncol Rep. 31:2660–2668. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang K, Zhu X, Zhang K, Zhu L and Zhou F:
FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant
A549 cells to docetaxel via activation of JNK/mitochondrial
pathway. Acta Biochim Biophys Sin. 48:804–809. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y
and Yu W: miR-134 inhibits epithelial to mesenchymal transition by
targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett.
586:3761–3765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma N, Zhang W, Qiao C, Luo H, Zhang X, Liu
D, Zang S, Zhang L and Bai J: The tumor suppressive role of
miRNA-509-5p by targeting FOXM1 in non-small cell lung cancer. Cell
Physiol Biochem. 38:1435–1446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Hock JM, Van Beneden RJ and Li X:
Aberrant overexpression of FOXM1 transcription factor plays a
critical role in lung carcinogenesis induced by low doses of
arsenic. Mol Carcinog. 53:380–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balli D, Zhang Y, Snyder J, Kalinichenko
VV and Kalin TV: Endothelial cell-specific deletion of
transcription factor FoxM1 increases urethane-induced lung
carcinogenesis. Cancer Res. 71:40–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
